司美格鲁肽中间体 29 肽,又名司美格鲁肽 29 肽主链、Semaglutide Intermediate P29、GLP-1(9-37), 是司美格鲁肽原料药合成的关键中间体。
司美格鲁肽钠盐是人胰高血糖素样肽-1 的一个长效类似物, 是人胰高血糖素样肽-1 (GLP-1) 受体的激动剂。Semaglutide 有潜力用于Ⅱ型糖尿病的研究。
本品是通过重组 DNA 技术和化学修饰的方法生产的一种长效胰高血糖素样肽-1(GLP-1)受体激动剂类似物,与人 GLP-1 相比,具有两处氨基酸替换,即 Ala8 替换为 Aib8(2-氨基异丁酸),Lys34 替换为 Arg34,在赖氨酸 26 处与脂肪二酸发生乙酰化,形成“司美格鲁肽”。
司美格鲁肽中间体 29 肽采用基因工程发酵方式生产,生产过程在GMP条件进行,产品纯度高。本品为大肠杆菌重组表达的司美格鲁肽前体,经酶切、层析纯化、冷冻干燥得到的冻干粉。
产品优势
无动物源:无动物病毒、无致病物质、无外源因子污染,安全性高。
合规性:生产设备和生产环境符合相关法规要求,符合GMP指导原则。
质量文件完整:按客户需求,可提供相关法规支持文件。
Semaglutide Intermediate 29‑peptide, also known as the main chain of Semaglutide 29‑peptide, Semaglutide Intermediate P29, or GLP‑1(9‑37), is a key intermediate for the synthesis of semaglutide active pharmaceutical ingredient (API).
Semaglutide sodium is a long‑acting analogue of human glucagon‑like peptide‑1 (GLP‑1) and an agonist of the human GLP‑1 receptor. Semaglutide holds potential for research on type 2 diabetes mellitus.This product is a long‑acting GLP‑1 receptor agonist analogue produced by recombinant DNA technology and chemical modification. Compared with human GLP‑1, it has two amino acid substitutions: Ala8 is replaced by Aib8 (2‑aminoisobutyric acid), and Lys34 is replaced by Arg34. Acetylation with fatty diacid occurs at lysine‑26 to form semaglutide.
Semaglutide Intermediate 29‑peptide is manufactured via genetic engineering fermentation under GMP‑compliant conditions with high product purity. It is a lyophilized powder obtained from Escherichia coli‑recombinantly expressed semaglutide precursor through enzymatic cleavage, chromatographic purification and freeze‑drying.
Product Advantages
Animal-origin Free: Free of animal viruses, pathogenic substances and adventitious agent contamination for superior safety.
Regulatory Compliance: Production facilities and manufacturing environment comply with relevant regulations and GMP guidelines.
Complete Quality Documentation: Relevant regulatory supporting documents are available upon customer request.